SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The index is trending amid volatility as traders weigh rising bond yields and geopolitical tensions against ongoing support from tech sector performance. Discussion remains fragmented, with bears focusing on a potential September correction while bulls anticipate continued momentum.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending amid ongoing debate over its long-term valuation, with investors weighing the company's significant contracted backlog and infrastructure buildout against macro-economic headwinds and market volatility. While some traders express frustration with the recent price consolidation, long-term investors emphasize strong fundamentals and the company's position as an AI data center builder.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

The discussion around SOXL is dominated by intense community frustration regarding the ETF's performance relative to its underlying semiconductor components, with many traders labeling it a 'scam' or 'rigged' due to perceived tracking errors and volatility. Investors are primarily focused on positioning ahead of upcoming Nvidia earnings and debating whether the current price action signals a deeper semiconductor correction or a potential bounce.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trading in a tight, range-bound pattern as traders weigh concerns over rising U.S. Treasury yields and geopolitical tensions against the resilience of mega-cap tech stocks. Market participants remain divided, with some betting on a seasonal September correction while others focus on continued institutional support for the AI sector.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is experiencing significant volatility and debate, with a recent collaboration update involving Panasonic and JANCTION sparking conflicting reactions. While some traders view the news as a positive catalyst for future utility and adoption, others remain skeptical, dismissing the project as a scam and pointing to poor price performance and lack of clear revenue impact.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors react to the company's autonomous vehicle progress, specifically the expansion of its Robotaxi fleet in Austin ahead of an upcoming product launch event. While bulls point to this momentum and robot-related developments as a positive catalyst, bears remain skeptical, framing the price action as a potential "sell the news" setup or an unsustainable speculative pump.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

SOXS is trending as traders debate the sustainability of the semiconductor sector's AI-driven rally, with many expressing bearish sentiment based on concerns over valuation, sector debt, and broader economic headwinds. Community sentiment remains polarized, with some traders actively shorting or buying the dip while others caution against the structural decay inherent in leveraged inverse ETFs.

Investment Managers Series Trust II - Tradr 2X Short NBIS Daily ETF

Tradr 2X Short NBIS Daily ETF

NBIZ is experiencing significant volatility as traders use the 2x leveraged inverse ETF to bet against NBIS, with the conversation dominated by intense debate over AI sector valuation, short-squeeze potential, and the risks of holding leveraged vehicles that suffer from volatility decay. While some traders report locking in profits from short-term price swings, others express frustration over the complex tracking of the fund during rapid market moves.

JinkoSolar Holding Co., Ltd. engages in the manufacture of solar modules. It distributes solar products and sells its solutions and services to a diversified international utility, commercial and residential customers. The company was founded by Xian De Li, Kang Ping Chen, and Xian Hua Li in June 2006 and is headquartered in Shangrao, China.

JinkoSolar Holding Co. Ltd - ADR

JinkoSolar Holding Co LTD

JinkoSolar is trending due to investor focus on its deeply discounted valuation, with many traders pointing to its large revenue base relative to its small market capitalization and the potential for a share buyback. While some investors express bullish sentiment regarding the company's technology leadership and energy storage potential, others remain cautious due to broader industry headwinds, including margin compression and market oversupply.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to positive Phase 3 clinical trial results for its LSD-based treatment in generalized anxiety disorder, which analysts indicate de-risks the company's lead asset and supports a multibillion-dollar commercial opportunity. While some traders debate the long-term scalability of in-clinic psychedelic therapy and the impact of a recent large equity offering, community sentiment remains largely bullish ahead of further trial results and anticipated regulatory milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit

10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Biosciences, prompting plans for an injunction.read more...

TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences

10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences PR Newswire PLEASANTON, Calif., Aug. 28, 2026 Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity...

SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future 

Equity

ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.

TXG August 2027 Options Begin Trading

Investors in 10x Genomics Inc (Symbol: TXG) saw new options begin trading today, for the August 2027 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 361 days until expiration the newly trading contrac...

10x Genomics (TXG) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Cathie Wood Bought The NVDA Dip Across Five Funds – Here’s What Else ARK Bought And Sold

ARKK and ARKG completely exited their respective positions in 10x Genomics.


10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up

TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outlook despite a year-over-year sales decline.

10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of +39.13% and +2.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

• Reported GAAP EPS of -$0.14 down -150.00% YoY
• Reported revenue of $151.04M down -12.65% YoY
• 10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $610 million to $630 million, representing 2% to 5% growth over 2025.

10x Genomics experienced a decline in total revenue and a shift to a net loss during the second quarter of 2026, while operating expenses increased significantly compared to the prior year.

10x Genomics improved gross margins through lower manufacturing costs and expanded its strategic capabilities and research footprint through the acquisition of Proteintech Genomics and new multi-year clinical research collaborations.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

10x Genomics Inc - Ordinary Shares - Class A

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

TXG 10x Genomics Inc - Ordinary Shares - Class A

Fundamentals

Connect Stocktwits to ChatGPT

Latest TXG News